Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab Plus PGemOx in R/R ENKTL
NCT05700448Phase 3Not yet recruiting
- Sponsor
- CStone Pharmaceuticals
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 3, randomised, double-blind trial in Extranodal NK/T-cell lymphoma (ENKTL) comparing Sugemalimab+PGemOx with Placebo+PGemOx (2 arms). Primary endpoint: Progression-Free Survival at 39 months. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
sugemalimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT05700448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700448.